Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 180M 0 159M 146M 137M 256M 17.03B 261M 1.75B 679M 8.39B 678M 663M 29.17B | P/E 2026 * |
11.5x | P/E 2027 * | 44.8x |
|---|---|---|---|---|---|
| Enterprise Value | 180M 0 159M 146M 137M 256M 17.03B 261M 1.75B 679M 8.39B 678M 663M 29.17B | EV / Sales 2026 * |
2.31x | EV / Sales 2027 * | 2.67x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 58 | 2019-06-29 |
Gilad Mamlok
DFI | Director of Finance/CFO | 58 | 2025-08-23 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 68 | 2019-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 73 | 2019-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 82 | 2014-10-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 180M | |
| +0.93% | +2.65% | +42.33% | +149.07% | 996B | |
| +1.61% | +7.22% | +60.81% | +49.65% | 580B | |
| +3.51% | +12.31% | +31.15% | +80.17% | 415B | |
| +5.66% | -2.44% | +22.01% | +15.66% | 326B | |
| +1.34% | +4.13% | +32.05% | +38.93% | 280B | |
| +1.09% | +4.38% | +36.10% | +23.11% | 284B | |
| +1.32% | +10.54% | -30.33% | -42.00% | 210B | |
| +0.40% | +4.51% | +25.85% | +57.00% | 190B | |
| -1.05% | +0.06% | +16.91% | +61.76% | 155B | |
| Average | +1.32% | +2.68% | +26.32% | +48.15% | 381.86B | |
| Weighted average by Cap. | +1.74% | +2.18% | +34.33% | +71.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78.3M 0 68.78M 63.37M 59.25M 111M 7.39B 113M 760M 294M 3.64B 294M 288M 12.66B | 67.56M 0 59.35M 54.68M 51.13M 95.89M 6.38B 97.65M 656M 254M 3.14B 254M 248M 10.92B |
| Net income | 15.72M 0 13.81M 12.72M 11.9M 22.31M 1.48B 22.72M 153M 59.13M 731M 59.04M 57.75M 2.54B | 4.07M 0 3.58M 3.3M 3.08M 5.78M 384M 5.89M 39.55M 15.32M 189M 15.3M 14.96M 658M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
